Spironolactone Tablet, Film Coated
Product Images NDC 43063-974

4 FDA label images from Pd-rx Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 43063-974). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

43063974 Label (43063974)

43063974 Label (43063974)
Label for Spironolactone USP 50 mg film coated tablets, containing 90 tablets per bottle. The product is labeled by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK, with NDC 43063-974-90. The label includes dosing instructions spaces, reorder number, lot number G20B89, and expiration date 11/2021, along with warnings and barcode information.*
FDA Label Image

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)
A Kaplan-Meier survival probability curve comparing Spironolactone (n=822) to Placebo (n=841) over a timeline of 0 to 48 months. The y-axis represents probability from 0 to 1, and the x-axis represents months. The graph shows a higher survival probability for Spironolactone compared to Placebo, with a reported log-rank p-value of less than 0.001.*
FDA Label Image

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)
A forest plot displaying hazard ratios and 95% confidence intervals for various subgroups comparing spironolactone versus placebo. The subgroups include age, sex, race, left ventricular ejection fraction (LVEF), heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The plot indicates whether spironolactone or placebo is favored across these categories.*
FDA Label Image

Chemical Structure (Spironolactone Structure Image)

Chemical Structure (Spironolactone Structure Image)
Chemical structure of spironolactone, showing its steroidal core with various functional groups including a lactone ring and thioacetate side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.